SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 22, 2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that the
Company is now permitted to apply the CE Mark to the
Diasensor 2000 Noninvasive Glucose Monitor, which has
software and hardware improvements over the Diasensor
1000 model and will be used in a telemedicine
healthcare management program for people with diabetes.
The CE Mark on the Diasensor signifies that the product
meets mandatory health and safety standards for medical
devices set by the European Union (EU) and may legally
be sold in its member countries.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 22, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL RECEIVES APPROVAL TO APPLY CE MARK TO DIASENSOR 2000
Pittsburgh, PA (May 22, 2000) - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that the Company is now permitted to
apply the CE Mark to the Diasensor 2000 Noninvasive Glucose
Monitor, which has software and hardware improvements over the
Diasensor 1000 model and will be used in a telemedicine
healthcare management program for people with diabetes.
The CE Mark on the Diasensor signifies that the product
meets mandatory health and safety standards for medical devices
set by the European Union (EU) and may legally be sold in its
member countries.
With the addition of a modem and custom software, the
Diasensor 2000 automatically downloads glucose readings to a
password-secured database, where charts of tests results can be
viewed by diabetic patients and their health care providers
through a standard Internet connection.
Biocontrol subsidiary, Diasensor.com, Inc., which owns the
patents and the worldwide marketing rights to the noninvasive
technology, is currently working with outside medical marketing
consultants to formulate its business plan to market in the EU
the telemedicine program incorporating the Diasensor 2000.
TUV Rheinland Product Safety GmbH, Cologne, Germany, an
organization recognized by the EU as a Notified Body for Product
Certification, granted the CE Mark approval. In order to be
permitted to apply the CE Mark to the Diasensor 2000 and to
market the device in the EU, the Company had to verify that its
device could meet the requirements of the EU's Medical Device
Directive (MDD) by undergoing TUV's audits and certification of
its quality system, rigorous safety testing, and clinical trials.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. The company's
subsidiaries include Diasensor.com, ViaCirQ, Inc. and Petrol Rem,
Inc. All are located in Pittsburgh, PA.
WEB SITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204
This press release contains statements of a forward-looking
nature. Shareholders and potential investors are cautioned
that such statements are predictions and actual events or results
may vary significantly.
###
